Dear Administrator Brooks-LaSure,

As members of the Heart Valve Disease Policy Task Force, a national group of 30 leaders including clinician and patient advocacy organizations, we appreciate the opportunity to respond to the CMS NCD Tracking Sheet regarding Tricuspid Valve Transcatheter Edge-to-Edge Repair (T-TEER), also known as the TriClip G4 System. Expanding Medicare coverage to include all FDA-approved minimally invasive transcatheter devices is essential for improving outcomes for patients suffering from symptomatic tricuspid regurgitation (TR).

Read full comment letter here.